“Fat” in this 2008 research story means lipid-like carrier molecules—not body fat or weight gain. Researchers called these materials lipidoids and investigated whether they could carry gene-silencing molecules into cells. The work showed preclinical results in cells and animals, not a human treatment.
What “fat” means in this story
The word refers to lipidoids: synthetic, lipid-like materials designed to help transport RNA molecules into cells. The term does not describe a change in body weight, an obesity finding, or a treatment involving dietary fat.
As an Amazon Associate I earn from qualifying purchases.
The study by Akin Akinc and colleagues, published online in Nature Biotechnology on 27 April 2008, introduced this approach to RNA delivery. The paper appeared in volume 26, pages 561–569.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Why RNA interference needs a delivery method
RNA interference (RNAi) can reduce the expression of selected genes. One widely used RNAi molecule is a short interfering RNA, or siRNA, which directs cellular machinery to target a matching messenger RNA. Messenger RNA carries instructions cells use to make proteins; reducing a target transcript can therefore reduce its expression.
#1 Best Overall
Getting an RNA molecule into a cell and to the machinery where it can act is a major practical challenge. The 2008 work focused on carriers that could help with that step, rather than on changing how RNAi recognizes its target.
What the researchers made and tested
A rapid synthesis and screening approach
Akinc and colleagues developed a rapid way to make and evaluate lipid-like materials, screening a library of more than 1,200 structurally diverse lipidoids. Some supported specific silencing of endogenous gene transcripts when formulated with siRNA or with antisense oligonucleotides targeting microRNA.
Experiments in cells and animals
The paper reports cell experiments and evaluation in mice, rats, and nonhuman primates. One example described in the contemporaneous news report used siRNA against factor VII, a blood-clotting factor expressed in the liver; researchers measured the target mRNA in blood and liver tissue. These are preclinical findings, not evidence of efficacy in people.
The authors argued that the materials might have broad utility for local and systemic delivery of RNA therapeutics. That was a prospect suggested by the preclinical work, not proof that every lipidoid could reach every tissue or serve as a treatment.
What the approach did not solve
The 2008 news report noted that the described lipidoids could not target delivery to specific cell types. Reaching a tissue or producing a measurable effect in an organ is not the same as selectively delivering an RNA molecule to one cell population within it. That distinction matters when an application requires precision.
The study also does not establish human safety, clinical benefit, or regulatory approval for this particular method. Its evidence comes from laboratory and animal work; it should be read as a delivery-technology advance, not as a demonstrated therapy.
Rank #4
- Used Book in Good Condition
Why the 2008 result mattered
The contribution was a way to rapidly generate and screen many candidate carriers, then identify materials that enabled RNA-based gene silencing in preclinical experiments. Chemistry World reported on the work on 28 April 2008, quoting researcher Daniel G. Anderson describing a synthesis process that could mix starting materials without solvent or multiple purification and protection steps. Simone Hess, who was developing RNAi therapeutics at the Max Planck Institute for Infection Biology, called the work “a big step forward.” Those comments reflect reactions to the research at the time, not claims of present-day clinical effectiveness.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11The enduring point in the headline is therefore about delivery: gene silencing got “fat” because researchers explored lipid-like carriers to help RNA reach cells. The reported advance was promising preclinical work, with cell-specific targeting still an unresolved limitation.
Quick Recap
Best Value
Sources
- Akinc et al., “A combinatorial library of lipid-like materials for delivery of RNAi therapeutics,” Nature Biotechnology, published online 27 April 2008.
- Chemistry World, “Gene silencing gets fat,” 28 April 2008.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
